Is it Worth Retaining QIAGEN Stock in Your Portfolio Now?
QIAGEN N.V.’s QGEN fourth-quarter performance was driven by solid potential in molecular diagnostics. The company continues to progress with its test menu expansion, building a solid foundation to ...
360Dx13d
Qiagen Sues BioMérieux in German Court for Infringing Tuberculosis Test Patent
Qiagen alleges that BioMérieux infringes a European patent that protects the company's QuantiFeron interferon-gamma release assay technology for latent TB detection.
Business Wire15d
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent in ...
Nasdaq15d
QIAGEN Files Patent Complaint Against BioMérieux To Protect QuantiFERON Technology
The patent, among several owned by QIAGEN that protect the QuantiFERON technology, encompasses significant innovations in the QuantiFERON-TB Gold Plus, which is employed worldwide for tuberculosis ...